Citations

Showing 10 of 108162 citations.

Ocular Relapse of B-Cell Acute Lymphoblastic Leukemia
Ferenchak, Kevin , Dao, Linda N. , Dalvin, Lauren A.

Mayo Clinic

JAMA Ophthalmology | April 21, 2021 | Volume: 139 | Issue: 4 | Pages: e210514

10.1001/jamaophthalmol.2021.0514 | PMID 33881496 Get It

Robert Wartenberg and the American Academy of Neurology
Boes, Christopher J. , Burkholder, David B , Boes, Christoper J , Burkholder, David B.

Mayo Clinic

Neurology | April 21, 2021 | Volume: 97 | Issue: 6 | Pages: 268-272

10.1212/wnl.0000000000012104 | PMID 33883241 Get It

ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma
Pedersen, Katrina S. , Foster, Nathan R. , Overman, Michael J. , Kim, Sunnie S., Arrambide, Kathryn A. , Jaszewski, Brandy L., Bekaii‐Saab, Tanios , Graham, Rondell P. , Welch, Jack, Wilson, Richard H. , Arrambide, Kathryn A , Graham, Rondell P , Welch, Jack , McWilliams, Robert R. , Bekaii-Saab, Tanios S , Pedersen, Katrina , Boland, Patrick M.

Mayo Clinic

Clinical Cancer Research | April 21, 2021 | Volume: 27 | Issue: 13 | Pages: 3641-3648

10.1158/1078-0432.ccr-21-0159 | PMID 33883178 Get It

Abstract Purpose: Small-bowel adenocarcinoma (SBA) is rare, and no standard of care exists for metastatic disease beyond first-line FOLFOX/CAPOX. SBA has higher rates of microsatellite instability (MSI-H) and T-lymphocyte infiltration than other gastrointestinal cancers. We hypothesize that pembrolizumab, a PD-1 inhibitor, will induce antitumor response. Patients and Methods: Patients with previously treated advanced SBA received pembrolizumab 200 mg i.v. every 3 weeks until disease progression (PD), toxicity, or 35 doses maximum. Primary endpoint was confirmed overall response rate (ORR) with secondary progression-free survival (PFS), overall survival (OS), and toxicity assessment endpoints. Outcomes were stratified by tumor location, microsatellite stability (MSS) or instability (MSI-H), and PD-L1 level. Results: Forty patients were treated for a median duration of four cycles (range, 1–35). All patients are off study treatment due to PD (75%), death (10%), 35 cycles completed (8%), refusal (3%), and adverse effects (AEs, 5%). Three confirmed partial responses [PRs; 8%; 95% confidence interval (CI), 2–20] did not meet predefined success criteria of ORR 30%. Median OS (7.1 months; 95% CI, 5.1–17.1) and median PFS (2.8 months; 95% CI, 2.7–4.2) were similar across primary tumor sites. One confirmed PR (3%) was seen in patients with low MSS/MSI tumors and correlated with high tumor mutation burden (TMB). Fifty percent of patients with MSI-H tumors achieved PR and remain alive without progression. Twenty-five patients (63%) had grade ≥3 AEs and 11 patients (28%) had grade 4/5 AEs. Conclusions: In the largest study of SBA to date, pembrolizumab did not induce the hypothesized response rate; however, we did identify responses in key biomarker-selected cohorts.
Right‐to‐left shunt detection using transforaminal insonation of the basilar artery
Chhabra, Nikita , Kumar, Gyanendra , Fruin, Jennifer, Dumitrașcu, Oana

Mayo Clinic

Journal of Neuroimaging | April 21, 2021 | Volume: 31 | Issue: 4 | Pages: 696-700

10.1111/jon.12855 | PMID 33878227 Get It

ABSTRACTBACKGROUND AND PURPOSEInvestigation for patent foramen ovale (PFO) is warranted in patients with cryptogenic stroke (CS), as PFO closure is recommended in select CS patients for secondary stroke prevention. Transcranial Doppler (TCD) is noninvasive and has high sensitivity for PFO screening. However, 10% of the population has insufficient temporal bone windows to perform standard TCD monitoring of the middle cerebral arteries (MCAs). Prior reports showed similar diagnostic accuracy between the basilar artery and MCAs insonation. Our objective was to assess the accuracy of transforaminal insonation of the basilar artery (TIBA) in diagnosis of right‐to‐left shunt (RLS) in patients with inadequate temporal windows.METHODSWe performed a retrospective, single‐center, observational study of TIBA in patients with CS and inadequate temporal windows. We compared the PFO screening accuracy using TIBA versus echocardiogram, either transthoracic (TTE) or transesophageal echocardiogram (TEE).RESULTSSixteen females and four males were included (mean age 63.2). All patients underwent TTE, 10 (50%) underwent gold‐standard TEE. Nine patients had positive PFO with both TCD and echocardiogram. Two patients with negative echocardiogram had TCD‐positive shunt. Three patients had PFO present on echocardiogram, whereas TCD was negative. Six patients had absent shunt with both TCD and echocardiogram. The sensitivity and specificity of TIBA for RLS detection were 75%, positive predictive value 82%, and negative predictive value 67%.CONCLUSIONPFO screening accuracy using TIBA was 75%. Prospective evaluation of CS patients with TIBA and comparison to the gold‐standard TEE should be performed to further guide clinical practice.
Faculty Opinions recommendation of Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Borlaug, Barry A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 21, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.739048449.793584438 Get It

Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2
Yadav, Devvrat , Khanna, Sahil

Mayo Clinic

Therapeutic Advances in Gastroenterology | April 21, 2021 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/17562848211009694 | PMID 33959193 Get It

Clostridioides difficile infection (CDI) is a consequence of flagrant use of antibiotics, an aging population with increasing comorbidities, and increased hospitalizations. The treatment of choice for CDI is antibiotics (vancomycin or fidaxomicin), with a possibility of recurrent CDI despite lack of additional risk factors for CDI. For the last 10 years, fecal microbiota transplantation (FMT) has emerged as a promising therapy for recurrent CDI, with success rates of over 85% compared with less than 50% with antibiotics for multiple recurrent CDI. Along with the success of FMT, several adverse and serious adverse events with FMT have been reported. These range from self-limiting abdominal pain to death due to severe sepsis. This review focuses on the safety of FMT, emphasizing the reports of transmission of pathobionts like extended-spectrum beta lactamase Escherichia coli and Shiga toxin-producing E. coli. The severe acute respiratory syndrome coronavirus-2 is a potential pathogen that could be transmitted via FMT during the COVID-19 pandemic. The challenges faced by clinicians for donor screening, clinical trials, and other aspects of FMT during the pandemic are discussed.
Faculty Opinions recommendation of Prenatal exposure to general anesthesia and childhood behavioral deficit.
Sviggum, Hans P.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 21, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.739433813.793584480 Get It

PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer
Chen, Chunhua , Li, Shiheng, Xue, Junli , Qi, Manlong, Liu, Xin , Hu, Jinghua , Dong, Haidong , Ling, Kun , Dong, Haidong , Huang, Yan

Mayo Clinic

JCI Insight | April 21, 2021 | Volume: 6 | Issue: 8 | Pages: No page available

10.1172/jci.insight.131458 | PMID 33884962 Get It

Although the immune checkpoint role of programmed death ligand 1 (PD-L1) has been established and targeted in cancer immunotherapy, the tumor-intrinsic role of PD-L1 is less appreciated in tumor biology and therapeutics development, partly because of the incomplete mechanistic understanding. Here we demonstrate a potentially novel mechanism by which PD-L1 promotes the epithelial-mesenchymal transition (EMT) in triple-negative breast cancer (TNBC) cells by suppressing the destruction of the EMT transcription factor Snail. PD-L1 directly binds to and inhibits the tyrosine phosphatase PTP1B, thus preserving p38-MAPK activity that phosphorylates and inhibits glycogen synthase kinase 3β (GSK3β). Via this mechanism, PD-L1 prevents the GSK3β-mediated phosphorylation, ubiquitination, and degradation of Snail and consequently promotes the EMT and metastatic potential of TNBC. Significantly, PD-L1 antibodies that confine the tumor-intrinsic PD-L1/Snail pathway restricted TNBC progression in immunodeficient mice. More importantly, targeting both tumor-intrinsic and tumor-extrinsic functions of PD-L1 showed strong synergistic tumor suppression effect in an immunocompetent TNBC mouse model. Our findings support that PD-L1 intrinsically facilitates TNBC progression by promoting the EMT, and this potentially novel PD-L1 signaling pathway could be targeted for better clinical management of PD-L1–overexpressing TNBCs.
Diagnostic yield, accuracy, and complication rate of CT-guided biopsy for spinal lesions: a systematic review and meta-analysis
Michalopoulos, Giorgos D. , Yolcu, Yagiz U. , Alvi, Mohammed Ali , Bydon, Mohamad , Yolcu, Yagiz Ugur, Bydon, Mohamad , Alvi, Mohammed Ali , Michalopoulos, Giorgos , Ghaith, Abdul Karim , Carr, Carrie M.

Mayo Clinic

Journal of NeuroInterventional Surgery | April 21, 2021 | Volume: 13 | Issue: 9 | Pages: 841-847

10.1136/neurintsurg-2021-017419 | PMID 33883210 Get It

Background CT-guided biopsy is a commonly used diagnostic procedure for spinal lesions. This meta-analysis aims to investigate its diagnostic performance and complications, as well as factors influencing outcomes. Methods A systematic review of the literature was performed to identify studies reporting outcomes of CT-guided biopsies for spinal lesions. Diagnostic yield (ie, the rate of procedures resulting in a specific pathological diagnosis) and diagnostic accuracy (ie, the rate of procedures resulting in the correct diagnosis) were the primary outcomes of interest. Complications following biopsy procedures were also included. Results Thirty-nine studies with 3917 patients undergoing 4181 procedures were included. Diagnostic yield per procedure was 91% (95% CI 88% to 94%) among 3598 procedures. The most common reason for non-diagnostic biopsies was inadequacy of sample. No difference in diagnostic yield between different locations and between lytic, sclerotic, and mixed lesions was found. Diagnostic yield did not differ between procedures using ≤13G and ≥14G needles. Diagnostic accuracy per procedure was 86% (95% CI 82% to 89%) among 3054 procedures. Diagnostic accuracy among 2426 procedures that yielded a diagnosis was 94% (95% CI 92% to 96%). Complication rate was 1% (95% CI 0.4% to 1.9%) among 3357 procedures. Transient pain and minor hematoma were the most common complications encountered. Conclusion In our meta-analysis of 39 studies reporting diagnostic performance and complications of CT-guided biopsy, we found a diagnostic yield of 91% and diagnostic accuracy of 86% with a complication rate of 1%. Diagnostic yield did not differ between different locations, between lytic, sclerotic and mixed lesions, and between wide- and thin-bore needles.
Laryngeal Sarcoidosis
Özgürsoy, Selmin Karataylı , Rutt, Amy, Rutt, Amy L.

Mayo Clinic

Ear, Nose & Throat Journal | April 21, 2021 | Volume: No volume available | Issue: No issue available | Pages: 014556132110125

10.1177/01455613211012583 | PMID 33881956 Get It